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etters to the Editor 
Dear Editor 
Corticosteroid treatment of asthma: now 
at the crossroads 
Anti-inflammatory corticosteroids have enjoyed a central 
role in the treatment of asthma for almost half a century; 
oral cortisone was first used in 1950 with good effect 
(1). Subsequent clinical trials revealed that corticosteroids 
were useful for treating exacerbations of asthma (2) and 
prednisone became the standard long-term treatment for 
patients with troublesome persistent symptoms. The typical 
side-effects associated with long-term oral treatment were 
traded off against the obvious benefits associated with 
better control of the asthma. 
The next major development came in 1972 (3); with the 
introduction of the inhaled corticosteroid, beclomethasone 
dipropionate (BDP): which became widely accepted 
standard therapy for patients whose asthma was 
inadequately controlled with bronchodilators. Initially the 
recommended doses were fairly modest (400-1000 pug 
day- ‘), but with favourable clinical experience the 
tendency (particularly in the U.K. and Australia) was to 
gradually increase the dosage (4), sometimes reaching 
2000 ,ug day - ’ or more in patients whose asthma was 
particularly difficult to control. 
As evidence accumulated that asthma is primarily an 
inflammatory disorder, it seemed rational to use inhaled 
corticosteroids to treat the underlying disorder. The enor- 
mous benefits of these drugs were quickly acknowledged, 
and at the time there was some justification for believing 
that the inhaled route of delivery would avoid significant 
systemic absorption provided the dose of BDP was below 
2OOOpg daily (5). When BDP first became available for 
clinical use laboratory assays for measuring drug concen- 
trations in plasma were not very sensitive, but with the 
recent advent of gas chromatography - mass spectrometry 
(GCMS) it is now possible to quantify anti-inflammatory 
corticosteroids in plasma after inhalation of doses that are 
well within the recommended therapeutic range (6). More- 
over, evidence that systemic drug absorption is sufficient to 
cause adverse effects has come from case reports in which 
Cushingoid features have developed in patients taking 
high-dose inhaled corticosteroids (7). 
In recent years, structural modifications of the cortico- 
steroid molecule have led to newer inhaled corticosteroids 
such as budesonide (BUD) and fluticasone propionate (FP); 
which are subject to greater first-pass hepatic metabolism, 
i.e. they have lower oral bioavailability. These kinetic 
differences reduce the contribution to overall systemic 
absorption from that part of the dose which is inadvertently 
swallowed during administration of inhaled corticosteroid. 
IIowever, although FP is inactivated extensively (99%) by 
first-pass hepatic metabolism (8), there is still significant 
systemic activity when it is given by inhalation in large 
doses (9). This observation highlights the fact that the lung 
is a very efficient route for systemic delivery of inhaled 
corticosteroids and that gastrointestinal absorption of drug 
that is swallowed rather than inhaled makes only a minor 
contribution to the total systemic bioavailability of an 
inhaled corticosteroid. 
Initial clinical studies with FP suggested that the strategy 
of structural modification of the steroid molecule may have 
yielded an inhaled corticosteroid with greater topical 
potency and less systemic activity than BDP or BUD (10). 
However, this attractive possibility overlooked some 
important weaknesses in the design of preliminary studies 
which had underestimated the difficulty in calculating rela- 
tive dose potency ratios for efficacy and systemic activity 
for different corticosteroids when most study designs had 
included only one or two doses of each drug. Reliable dose 
potency ratios for comparison of drugs within the same 
class can only be obtained from studies that include mul- 
tiple doses across the full dose-response range and make 
appropriate adjustments for placebo effects and diurnal 
changes in pulmonary function and cortisol production. 
A recently published randomized placebo-controlled trial 
of the two newest inhaled corticosteroids (BUD and FP) 
involved administration of multiple doses of each of these 
drugs to 28 normal volunteers in a seven-way cross-over 
design (11). Repeated blood samples for measurement of 
plasma cortisol were taken over a 24-h period to determine 
the area under the curve (AUC,,) after 4 days of treatment 
with each of three doses of BUD and three doses of FP. The 
surprising finding was that even modest doses of BUD and 
FP, which equate to those routinely prescribed for many 
patients with asthma (800 mcg d - ’ budesonide and 
500 mcg d ~ i fluticasone), caused a discernible reduction in 
plasma cortisol AUC,,. In addition, dose-response analysis 
showed that, on a microgram-for-microgram nominal dose 
basis, the potency ratio for the systemic activity of FP 
relative to BUD was 3:1, which marginally exceeds the 
reported efficacy ratio of approximately 2:l (10). 
This leaves us with the disappointing impression that 
development of a more potent inhaled corticosteroid by 
molecular structural modification is insufficient to materi- 
ally improve the topical-to-systemic activity ratio; which 
relates clinically to the overall risk-benefit profile, mainly 
because the lung is such an eficient route for systemic drug 
delivery. 
The advent of anti-leukotriene drugs, the first of which 
(montelukast, zafirlukast and zileuton) are now avail- 
able, offers an alternative novel approach to the long-term 
treatment of the underlying inflammation of asthma (12). 
Whilst it has been usual practice in the past to develop 
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inhaled formulations of anti-asthma drugs to direct them to 
the site of action, many pharmaceutical companies have 
elected to develop the initial anti-leukotriene drugs as oral 
formulations, presumably because of patient preference 
with this route of administration in the large U.S. and 
Japanese markets. The availability of this new class of 
anti-leukotriene drugs should prompt the pharmaceutical 
industry to escalate its efforts to discover topically active 
corticosteroids which have minimal systemic effect, either 
by intensified endeavours in medicinal chemistry or by 
some alteration to the pharmaceutical formulation such 
that the effects of the inhaled drug are confined to the lung. 
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Reply to Drs Seale and Donnelly 
Drs Seale and Donnelly make several important points 
regarding the challenge inhaled glucocorticoids now face 
with the introduction of leukotriene modifiers (1). How- 
ever, it is the opinion leaders who are at the crossroads and 
face the challenge in defining the appropriate management 
for asthma. In recent years, opinion leader teams or 
‘expert panels’ have profiled inhaled glucocorticoids as the 
‘preferred’ long-term asthma control medication (2,3). 
Numerous studies show that inhaled glucocorticoids 
improve overall asthma management, reduce the need for 
rescue bronchodilator therapy, and reduce hospitalizations 
(4-7). They also improve pulmonary function and reduce 
airways hyperresponsiveness with long-term treatment 
(4-5). Recent observations suggest that the response to 
inhaled glucocorticoids is highly dependent on the time of 
intervention, the earlier used the better (5,7-9). These 
observations have raised the question whether delays in 
intervention, specifically with inhaled glucocorticoids, lead 
to irreversible or incompletely reversible changes in airway 
pathology. 
The inhaled glucocorticoids as a class, however, face a 
formidable challenge to retain their position as the pre- 
ferred medication for long-term asthma control. Their 
effect is limited to the duration of treatment (5), they do not 
induce remission, and the response to glucocorticoids can 
vary among patients (10). In addition, recent reports have 
raised concern regarding the risk of adverse effects with 
long-term high-dose inhaled glucocorticoid therapy (11,lZ). 
Attempts to compare the various inhaled glucocorticoids 
have placed emphasis on measures of cortisol suppression 
and have consequently drawn attention to the systemic 
effects of all inhaled glucocorticoids. Indeed, Seale and 
Donnelly’s report utilizes cortisol suppression to derive 
potency ratios for the systemic effect of two inhaled gluco- 
corticoids (1). Unfortunately, this type of information has 
not defined a ‘preferred’ inhaled glucocorticoid. It appears 
that as the potency of an inhaled glucocorticoid increases in 
relation to efficacy, there appears to be a corresponding 
increase in potency on cortisol suppression. Putting the two 
measures together, that is, efficacy and systemic effect 
potency, could lead to the development of a therapeutic 
index. Attempts to define this therapeutic index have not 
been successful, but studies are now in progress under the 
direction of the National Heart, Lung and Blood Institute 
Asthma Clinical Research Network. 
Other medications described as ‘controllers’ prevent 
symptoms and improve pulmonary function, but do no 
resolve airways inflammation, for example long-acting 
b-agonists. Interest has grown in the leukotriene modifier 
class of long-term asthma controllers. In the U.S.A., three 
